Important messages:
15 excess deaths in first 3 months (5% out of 292 patients) in nivolumab arm
Patients in the nivolumab arm dying in the first 3 months
tended to have
more poor prognostic factors along with no / low PDL-1 expression
Patient in the nivolumab arm surviving beyond 3 months did well whether
PDL-1 expression was low or high
